Artizan Biosciences
Artizan Biosciences, Inc. (labs in New Haven; HQ in Durham, NC) was launched with the discovery made by founders Dr. Richard Flavell, Noah Palm, PhD, and Marcel de Zoete, PhD in Yale’s Department of Immunobiology that they could distinguish certain pathogenic bacteria from the remainder of the intestinal microbiota. The ability to target these specific bacteria could lead to treatment options for a number of digestive disorders as well as other diseases including obesity, autoimmune disease, and a wide variety of skin, lung and central nervous system (CNS) diseases. Hatteras Ventures Partners is the lead investor.